|
注册号: Registration number: |
ChiCTR2500113298 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-26 18:33:56 |
|
注册时间: Date of Registration: |
2025-11-26 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于循证的股骨撞击综合症患者术前预康复方案的构建与应用 |
|
Public title: |
Construction and application of evidence-based pre-operation rehabilitation program for patients with femur impingement syndrome |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于循证的股骨撞击综合症患者术前预康复方案的构建与应用 |
|
Scientific title: |
Construction and application of evidence-based pre-operation rehabilitation program for patients with femur impingement syndrome |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陆晟迪 |
研究负责人: |
李敏 |
|
Applicant: |
Lu Sheng Di |
Study leader: |
Min Li |
|
申请注册联系人电话: Applicant telephone: |
+86 139 1648 2184 |
研究负责人电话:
Study leader's |
+86 189 3017 4976 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lushendi0828@163.com |
研究负责人电子邮件: Study leader's E-mail: |
18930173559@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市宜山路600号 |
研究负责人通讯地址: |
上海市宜山路600号 |
|
Applicant address: |
No 600 Yishan Road, Shanghai |
Study leader's address: |
No 600 Yishan Road, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属第六人民医院 |
||
|
Applicant's institution: |
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属第六人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-KY-217(K) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第六人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Sixth People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-09 00:00:00 | ||
|
伦理委员会联系人: |
曾炳方 |
||
|
Contact Name of the ethic committee: |
Zeng Bing Fang |
||
|
伦理委员会联系地址: |
上海市宜山路600号 |
||
|
Contact Address of the ethic committee: |
No 600 Yishan Road, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6436 9181 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院附属第六人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市宜山路600号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No 600 Yishan Road, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financed |
||||||||||||||||||||||
|
研究疾病: |
髋关节撞击症 |
||||||||||||||||||||||
|
Target disease: |
Femoroacetabular impingement |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评估髋关节股骨髋臼撞击(FAI)手术前康复(术前康复)项目的效果 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effects of a presurgical rehabilitation (preoperative rehabilitation) program for hip femoral acetabular impingement (FAI) |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 其他髋关节病史,如Perthes病、股骨头骨骺滑脱、股骨头缺血性坏死或严重骨关节炎。 2. 既往患侧髋关节手术史。 3. 神经肌肉或系统性疾病。 4. 无法提供知情同意或依从研究方案。 5. 妊娠期妇女及参与其他冲突临床研究的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Other hip history, such as Perthes disease, epiphyseal slip of the femoral head, avascular necrosis of the femoral head, or severe osteoarthritis. 2. Previous history of hip surgery on the affected side. 3. Neuromuscular or systemic diseases. 4. Failure to provide informed consent or comply with the study protocol. 5. Pregnant women and patients participating in other conflict clinical studies. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-01 00:00:00至 To 2026-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-10-01 00:00:00 至 To 2025-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
在SAS/STAT 9.3 (SAS Institute, Cary, North Carolina)中使用SAS Proc Plan创建计算机生成的随机列表。统计学家准备了这份清单,并将其放在一系列密封的信封中分发给每个站点的临床协调员。随后,研究协调员在患者在场的情况下进行随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A computer-generated randomization list was created using SAS Proc Plan in SAS/STAT 9.3 (SAS Institute, Cary, North Carolina). The statistician prepared this list and distributed it to each site's clinical coordinator in a series of sealed envelopes. Subsequently, the study coordinator conducted the randomization in the presence of the patient. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
负责分析数据的个人也将对分组分配进行盲法。数据将在分析前匿名化,以确保在统计评估过程中不泄露治疗分配。 |
|
Blinding: |
The individuals responsible for analyzing the data will be blinded to the group allocation as well. Data will be anonymized prior to analysis, ensuring that the treatment allocation is not revealed during the statistical evaluation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究主要论文发表一年后以授权访问形式共享原始数据库:http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Share the original database with authorized access one year after publication of the main research paper |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集和管理由病例记录表(Case Record Form, CRF)和电子数据采集和管理系统(Electronic Data Capture, EDC)两部分共同实施。研究者在患者访视时根据研究方案规范填写纸质CRF,内容包括人口学信息、基线特征、治疗方案、随访评估指标以及不良事件等各项数据。完成填写后,研究人员在规定的时限内,将纸质CRF中的信息准确录入至EDC系统。数据录入完成后,质控人员通过EDC系统内置的逻辑检查、范围核查、数据一致性比对等功能,及时发现问题并进行数据质疑,研究人员核实后予以修正和确认。所有数据均通过定期备份确保安全存储,且严格限制访问权限。整个过程中,由专人负责数据备份和管理,确保数据的安全性、完整性和可追溯性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and management are implemented by the Case Record Form (CRF) and the Electronic Data Capture and Management System (EDC). At the time of patient visit, researchers filled in paper CRF according to the study protocol specification, including demographic information, baseline characteristics, treatment regimen, follow-up evaluation indicators, adverse events and other data. After completing the filling, the researchers accurately input the information in the paper CRF into the EDC system within the prescribed time limit. After the data entry is completed, the quality control personnel will find the problem in time and question the data through the built-in functions of the EDC system such as logic check, scope check and data consistency comparison, and the researchers will correct and confirm it after verification. All data is stored securely with regular backups, and access is strictly restricted. During the whole process, a dedicated person is responsible for data backup and management to ensure data security, integrity and traceability. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |